Post-operative Ovarian Adhesion Study in Women With Endometriosis
Recruitment status was Not yet recruiting
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Effectiveness of Anti-adhesive Gel in Preventing Post Operative Ovarian Adhesions in Women With Pelvic Endometriosis: A Double Blind Randomized Controlled Trial|
- The prevalence of ovarian adhesions diagnosed by ultrasound after laparoscopic surgery [ Time Frame: Ultrasound assessment 3 months post-surgery ] [ Designated as safety issue: No ]The primary outcome measure is the prevalence of ovarian adhesions diagnosed by ultrasound assessment after surgery. The presence of ovarian adhesions will be assessed by a combination of gentle pressure with the vaginal probe and abdominal pressure with the examiner's free hand as in a bimanual examination. The prevalence of ovarian adhesions will be diagnosed when the ovarian mobility is restricted and the ovary cannot be separated from the peritoneum of the lateral pelvic side wall and/or pouch of Douglas.
- The presence, intensity and site of post operative pain [ Time Frame: Assessed at 3 months post-operative review ] [ Designated as safety issue: No ]
|Study Start Date:||December 2013|
|Estimated Study Completion Date:||April 2015|
|Estimated Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
Device: Anti-adhesive gel
4mls of anti-adhesive gel coated to the randomized ovary
Endometriosis is a common benign condition, affecting women of reproductive age. The disorder is characterized by endometrial surface epithelium, endometrial glands or stroma, found outside the uterus at anatomically ectopic sites.
- Laparoscopic excision of the disease is frequently carried out for the treatment of severe endometriosis. Pelvic adhesions often develop following surgery, restricting the success of treatment. Commercially available anti-adhesive solutions are often used successfully for limiting post-operative adhesions following myomectomy surgery.
- This study aims to assess the effect of resorbable hydrogel anti-adhesive gel following laparoscopic surgery for severe pelvic endometriosis on the prevalence of postoperative ovarian adhesions.
- This is a prospective double blind randomized controlled trial for patients with severe pelvic endometriosis (as defined by the American Society for Reproductive Medicine classification system) requiring extensive laparoscopic dissection (open of one or both para-rectal spaces) with uterine and ovarian preservation.
- Disease severity and eligibility for inclusion into the study will be confirmed at surgery.
- Pre-operatively, all participants will complete a standardized symptom questionnaire detailing the presence and intensity of specific endometriosis symptoms Intra-operatively both ovaries are routinely elevated to the anterior abdominal wall using Prolene suture (ovarian suspension) to facilitate operative access. At the end of the procedure, each participant will be randomized to having only one ovary coated with 4mls of hydrogel anti-adhesive gel, before the ovaries are replaced to their anatomically correct position.
- Three months after surgery, all randomized patients will have a transvaginal ultrasound scan to assess for ovarian mobility and repeat symptom questionnaire.
- Both patients and the person performing the ultrasound scan will be blinded to the randomization process.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01989260
|Contact: Katie Patemanfirstname.lastname@example.org|
|Contact: Davor Jurkovicemail@example.com|
|University College London Hospital||Not yet recruiting|
|London, England, United Kingdom, NW1 2BU|
|Contact: Katie Pateman firstname.lastname@example.org|
|Contact: Davor Jurkovic email@example.com|
|Principal Investigator: Katie Pateman|
|Principal Investigator: Davor Jurkovic|
|Sub-Investigator: Alfred Cutner|
|Sub-Investigator: Ertan Saridogan|
|Sub-Investigator: George Pandis|
|Sub-Investigator: Tom Holland|
|Study Director:||Davor Jurkovic||University College London Hospital|
|Study Chair:||Ertan Saridogan||University College London Hospital|
|Study Chair:||Alfred Cutner||University College London Hospital|
|Study Chair:||George Pandis||University College London Hospital|